Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2385-2398

  Leszczynska, Katarzyna B ^a   Foskolou, Iosifina P ^a   Abraham, Aswin G ^a   Anbalagan, Selvakumar ^a   Tellier, Céline ^a   Haider, Syed ^a   Span, Paul N ^b   O'Neill, Eric E ^a   Buffa, Francesca M ^a   Hammond, Ester M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; B CELL TRANSLOCATION GENE 2; CASPASE 3; CYTOPLASMIC FMR1 INTERACTING PROTEIN 2; KN MOTIF AND ANKYRIN REPEAT DOMAINS 3; PLECKSTRIN; PLECKSTRIN DOMAIN CONTAINING A3; PROTEIN; PROTEIN BAX; PROTEIN BID; PROTEIN KINASE B; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; SMALL INTERFERING RNA; SULFATASE; SULFATASE 2; SYNAPTOJANIN; UNCLASSIFIED DRUG; BTG2 PROTEIN, HUMAN; CARRIER PROTEIN; CYFIP2 PROTEIN, HUMAN; IMMEDIATE EARLY PROTEIN; INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; KANK3 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHATASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SULF2 PROTEIN, HUMAN; SULFOTRANSFERASE; TP53 PROTEIN, HUMAN; TSSC3 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; DOWN REGULATION; EMBRYO; EMBRYONIC STEM CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE TEST; KIDNEY CANCER; MELANOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ACETYLATION; RADIOSENSITIVITY; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TRANSACTIVATION; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; CELL HYPOXIA; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; RADIATION DOSE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CARRIER PROTEINS; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; IMMEDIATE-EARLY PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; SULFOTRANSFERASES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84930403357     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80402     Document Type: Article

References (61)

1. McKeown SR. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol. 2014;87(1035): 20130676.
2. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11(4): 239-253.
3. Hockel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93(4): 266-276.
4. Buffa FM, Harris AL, West CM, Miller CJ. Large meta-Analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer. 2010;102(2): 428-435.
5. Chitneni SK, Palmer GM, Zalutsky MR, Dewhirst MW. Molecular imaging of hypoxia. J Nucl Med. 2011;52(2): 165-168.
6. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 1989;49(23): 6449-6465.
7. Olcina MM, et al. Replication stress and chromatin context link ATM activation to a role in DNA replication. Mol Cell. 2013;52(5): 758-766.
8. Mazouzi A, Velimezi G, Loizou JI. DNA replication stress: Causes, resolution and disease. Exp Cell Res. 2014;329(1): 85-93.
9. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol. 2002;22(6): 1834-1843.
10. Brady CA, Attardi LD. p53 at a glance. J Cell Sci. 2010;123(pt 15): 2527-2532.
11. Graeber TG, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379(6560): 88-91.
12. Brosh R, Rotter V. When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer. 2009;9(10): 701-713.
13. Hammond EM, Dorie MJ, Giaccia AJ. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem. 2003;278(14): 12207-12213.
14. Alarcon R, Koumenis C, Geyer RK, Maki CG, Giaccia AJ. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 1999;59(24): 6046-6051.
15. Lee JH, et al. Hypoxia activates tumor suppressor p53 by inducing ATR-Chk1 kinase cascade-mediated phosphorylation and consequent 14-3-3? inactivation of MDMX protein. J Biol Chem. 2012;287(25): 20898-20903.
16. Hammond EM, Giaccia AJ. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun. 2005;331(3): 718-725.
17. Soengas MS, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 1999;284(5411): 156-159.
18. Hammond EM, et al. Genome-wide analysis of p53 under hypoxic conditions. Mol Cell Biol. 2006;26(9): 3492-3504.
19. Johnson TM, Hammond EM, Giaccia A, Attardi LD. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat Genet. 2005;37(2): 145-152.
20. Li YZ, Lu DY, Tan WQ, Wang JX, Li PF. p53 initiates apoptosis by transcriptionally targeting the antiapoptotic protein ARC. Mol Cell Biol. 2008;28(2): 564-574.
21. Koumenis C, et al. Regulation of p53 by hypoxia: Dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol. 2001;21(4): 1297-1310.
22. Fei P, et al. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell. 2004;6(6): 597-609.
23. Brady CA, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 2011;145(4): 571-583.
24. Li T, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149(6): 1269-1283.
25. Valente LJ, et al. p53 efficiently suppresses tumor development in the complete absence of its cellcycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 2013;3(5): 1339-1345.
26. Kenzelmann Broz D, et al. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev. 2013;27(9): 1016-1031.
27. Mellert HS, et al. Deacetylation of the DNA-binding domain regulates p53-mediated apoptosis. J Biol Chem. 2011;286(6): 4264-4270.
28. Adamsen BL, Kravik KL, Clausen OP, De Angelis PM. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol. 2007;31(6): 1491-1500.
29. Hong JW, Ryu MS, Lim IK. Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces Pin-1 binding in cytoplasm and cell death. J Biol Chem. 2005;280(22): 21256-21263.
30. Mongroo PS, et al. IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2. Cancer Res. 2011;71(6): 2172-2182.
31. Kerley-Hamilton JS, Pike AM, Li N, DiRenzo J, Spinella MJ. A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene. 2005;24(40): 6090-6100.
32. Kawase T, et al. PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell. 2009;136(3): 535-550.
33. Jackson RS 2nd, Cho YJ, Stein S, Liang P. CYFIP2, a direct p53 target, is leptomycin-B sensitive. Cell Cycle. 2007;6(1): 95-103.
34. Chau BN, et al. Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. Cancer Res. 2009;69(4): 1368-1374.
35. Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis. 2011;2: E164.
36. Lion M, et al. Interaction between p53 and estradiol pathways in transcriptional responses to chemotherapeutics. Cell Cycle. 2013;12(8): 1211-1224.
37. Tu Z, et al. Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein. Blood. 2001; 98(7): 2028-2038.
38. Miller LD, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102(38): 13550-13555.
39. Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486(7403): 346-352.
40. Silwal-Pandit L, et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res. 2014;20(13): 3569-3580.
41. Liu Q, et al. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 1999;13(7): 786-791.
42. Brooks R, et al. SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells. J Immunol. 2010;184(7): 3582-3589.
43. Chen EY, Mazure NM, Cooper JA, Giaccia AJ. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 2001;61(6): 2429-2433.
44. Stegeman H, et al. Activation of AKT by hypoxia: A potential target for hypoxic tumors of the head and neck. BMC Cancer. 2012;12(1): 463.
45. Yao W, et al. Association of p53 expression with prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7(10): 7158-7163.
46. Ohki R, et al. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A. 2014;111(23): E2404-E2413.
47. Cheung EC, Ludwig RL, Vousden KH. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc Natl Acad Sci U S A. 2012; 109(50): 20491-20496.
48. Viernes DR, Choi LB, Kerr WG, Chisholm JD. Discovery and development of small molecule SHIP phosphatase modulators. Med Res Rev. 2014;34(4): 795-824.
49. Wennemers M, et al. Hypoxia regulation of phosphokinases and the prognostic value of pAKT in breast cancer. Int J Biol Markers. 2013;28(2): 151-160.
50. Stiles BL. PI-3-K and AKT: Onto the mitochondria. Adv Drug Deliv Rev. 2009;61(14): 1276-1282.
51. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs. 2010;19(11): 1355-1366.
52. Fruman DA, Rommel C. PI3K and cancer: Lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13(2): 140-156.
53. Diaz R, et al. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Br J Cancer. 2009;100(6): 932-940.
54. Chen W, Wu S, Zhang G, Wang W, Shi Y. Effect of AKT inhibition on epithelial-mesenchymal transition and ZEB1-potentiated radiotherapy in nasopharyngeal carcinoma. Oncol Lett. 2013;6(5): 1234-1240.
55. Zhang T, et al. Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation. Oncol Rep. 2010;24(6): 1683-1689.
56. Prevo R, et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res. 2008;68(14): 5915-5923.
57. Hamilton G, et al. AKT regulates NPM dependent ARF localization p53mut stability in tumors. Oncotarget. 2014;5(15): 6142-6167.
58. Fokas E, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 2012;72(1): 239-248.
59. Bencokova Z, Kaufmann MR, Pires IM, Lecane PS, Giaccia AJ, Hammond EM. ATM activation and signaling under hypoxic conditions. Mol Cell Biol. 2009;29(2): 526-537.
60. Benjamini Y, Hochberg Y. Controlling the false discovery rate - A practical and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995;57(1): 289-300.
61. Pastorek J, et al. Cloning and characterization of MN, a human tumor-Associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994;9(10): 2877-2888.